InterAction Database (IADB)
Description
The InterAction Database includes demographic and prescription information for more than 500,000 patients in the northern and middle Netherlands and has been integrated with other systems to enhance data collection and analysis. No specific mention was made of the inclusion of information on cancer-related outcomes.
Selected References
Utilization
Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TC, de Jong-van den Berg LT. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study
. Br J Clin Pharmacol. 2005 Dec;60(6):641-7.
Cost/Cost Effectiveness
Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther. 2004 Apr;26(4):579-89.
Treatment/Survivorship
Kho Y, Jansman FG, Prins NH, Neef C, Brouwers JR. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit. 2006 Apr;28(2):206-11.
Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clin Ther. 2005 Mar;27(3):327-35.
Jansman FG, Jansen AJ, Coenen JL, de Graaf JC, Smit WM, Sleijfer DT, Brouwers JR. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer. Am J Health Syst Pharm. 2005 Sep 1;62(17):1788-93.